April 12, 2010 - Ampio Pharmaceuticals Contracts with St. Michael's Hospital to Conduct Phase II Clinical Trial of Optina™ to Treat Diabetic Retinopathy - Ampio Pharmaceuticals, Inc. (OTCBB: AMPE), announced the signing of a contract with St. Michael's Hospital, Toronto, Canada to conduct, "A Randomized, Placebo-Controlled, Parallel Treatment Group, Double-Masked Study to Evaluate the Efficacy and Safety of Three Doses of Oral Optina™ in Adult Subjects with Diabetic Macular Edema". This phase II trial will seek the optimal content of each dose using industry standard methods of Optical Coherence Tomography (OCT) and Best Corrected Visual Acuity (BCVA). The data will be used to construct a pivotal phase III trial for submission to regulatory bodies in the USA, Europe and Asia... Ampio Pharmaceuticals' Press Release -
Tuesday, April 27, 2010
Ampio Pharmaceuticals : Phase II Clinical Trial of Optina™ to Treat Diabetic Retinopathy
April 12, 2010 - Ampio Pharmaceuticals Contracts with St. Michael's Hospital to Conduct Phase II Clinical Trial of Optina™ to Treat Diabetic Retinopathy - Ampio Pharmaceuticals, Inc. (OTCBB: AMPE), announced the signing of a contract with St. Michael's Hospital, Toronto, Canada to conduct, "A Randomized, Placebo-Controlled, Parallel Treatment Group, Double-Masked Study to Evaluate the Efficacy and Safety of Three Doses of Oral Optina™ in Adult Subjects with Diabetic Macular Edema". This phase II trial will seek the optimal content of each dose using industry standard methods of Optical Coherence Tomography (OCT) and Best Corrected Visual Acuity (BCVA). The data will be used to construct a pivotal phase III trial for submission to regulatory bodies in the USA, Europe and Asia... Ampio Pharmaceuticals' Press Release -
